VHC · Insider Trading
VirnetX Holding Corp Common Stock
Every open-market purchase and sale reported by VHC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Michael F Angelo | Director | Sell | −1,000 | −$10.26K |
| 2026-09-14 | Kendall Larsen | President & CEO | Sell | −20,425 | −$232.29K |
| 2026-09-02 | Gary Feiner | Director | Sell | −7,500 | −$83.15K |
| 2026-09-02 | Kendall Larsen | President & CEO | Sell | −14,575 | −$163.48K |
| 2026-07-13 | Katherine Allanson | Chief Financial Officer | F | −100 | −$1.20K |
| 2026-06-25 | Thomas M O'Brien | Director | A | +7,500 | — |
| 2026-06-15 | Gary Feiner | Director | A | +7,500 | — |
| 2026-06-15 | Michael F Angelo | Director | A | +7,500 | — |
| 2026-06-15 | Heidy Kingwan Chow | Director | A | +7,500 | — |
| 2025-12-03 | Thomas M O'Brien | Director | M | +625 | +$6.31K |
| 2025-11-26 | Michael F Angelo | Director | Sell | −625 | −$13.06K |
| 2025-11-26 | Kendall Larsen | President & CEO | A | +80,000 deriv. | — |
| 2025-11-26 | Katherine Allanson | Chief Financial Officer | A | +30,000 deriv. | — |
| 2025-11-26 | Gary Feiner | Director | Sell | −1,875 | −$42.56K |
| 2025-07-11 | Katherine Allanson | Chief Financial Officer | F | −102 | −$1.26K |
| 2025-07-11 | Robert D Short III | Chief Scientist | F | −50 | −$617 |
| 2025-06-25 | Robert D Short III | Chief Scientist | F | −8 | −$64 |
| 2025-06-16 | Thomas M O'Brien | Director | A | +7,500 | — |
| 2025-06-16 | Heidy Kingwan Chow | Director | A | +7,500 | — |
| 2025-06-16 | Michael F Angelo | Director | A | +7,500 | — |
| 2025-06-16 | Gary Feiner | Director | A | +7,500 | — |
| 2024-11-14 | Katherine Allanson | Chief Financial Officer | A | +30,000 | — |
| 2024-11-14 | Robert D Short III | Chief Scientist | A | +30,000 | — |
| 2024-11-14 | Kendall Larsen | President & CEO | A | +80,000 | — |
| 2024-06-18 | Michael F Angelo | Director | A | +7,500 | — |
| 2024-06-18 | Thomas M O'Brien | Director | A | +7,500 | — |
| 2024-06-18 | Gary Feiner | Director | A | +7,500 | — |
| 2024-06-18 | Heidy Kingwan Chow | Director | A | +22,500 | — |
| 2024-05-29 | Kendall Larsen | President & CEO | Buy | +1,000 | +$4.14K |
| 2024-05-23 | Kendall Larsen | President & CEO | Buy | +2,135 | +$9.93K |
| 2024-04-25 | Darl C McBride | Chief Operating Officer | F | −2,135 | −$13.86K |
| 2024-01-03 | Darl C McBride | Chief Operating Officer | A | +6,000 | — |
| 2023-07-07 | Katherine Allanson | Chief Financial Officer | A | +28,150 | — |
| 2023-07-07 | Robert D Short III | Chief Scientist | A | +28,150 | — |
| 2023-07-07 | Kendall Larsen | President & CEO | A | +84,450 | — |
| 2023-06-20 | Thomas M O'Brien | Director | A | +8,333 | — |
| 2023-06-20 | Gary Feiner | Director | A | +8,333 | — |
| 2023-06-20 | Michael F Angelo | Director | A | +8,333 | — |
| 2023-06-07 | Kendall Larsen | President & CEO | Buy | +27,974 | +$10.63K |
| 2023-05-31 | Kendall Larsen | President & CEO | Buy | +2,000 | +$860 |
| 2023-05-30 | Michael F Angelo | Director | Buy | +23,000 | +$9.89K |
| 2023-05-22 | Kendall Larsen | President & CEO | Buy | +104,166 | +$46.71K |
| 2023-05-19 | Thomas M O'Brien | Director | Buy | +50,000 | +$21.00K |
| 2022-06-14 | Thomas M O'Brien | Director | A | +8,333 | — |
| 2022-06-14 | Kendall Larsen | President & CEO | A | +40,004 | — |
| 2022-06-14 | Michael F Angelo | Director | A | +8,333 | — |
| 2022-06-14 | Robert D Short III | Chief Scientist | A | +13,336 | — |
| 2022-06-14 | Gary Feiner | Director | A | +8,333 | — |
| 2022-05-26 | Kendall Larsen | President & CEO | Buy | +15,699 | +$18.71K |
| 2022-05-24 | Kendall Larsen | President & CEO | Buy | +43,081 | +$51.70K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kendall Larsen | President & CEO | 418,707 | $4.37M |
| Robert D Short III | Chief Scientist | 43,126 | $449.80K |
| Heidy Kingwan Chow | Director | 37,500 | $391.12K |
| Thomas M O'Brien | Director | 35,457 | $369.82K |
| Katherine Allanson | Chief Financial Officer | 31,205 | $325.47K |
| Michael F Angelo | Director | 28,209 | $294.22K |
| Gary Feiner | Director | 16,874 | $176.00K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VHC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.